Lund R H, Moritz M W
Arch Surg. 1982 Jul;117(7):924-8. doi: 10.1001/archsurg.1982.01380310038009.
The records of 49 consecutive patients treated with Denver peritoneovenous shunts were reviewed to determine the incidence of complications and length of patient survival. Thirty-eight complications (16 types) were identified in 22 (45%) of the patients and, in 10 instances, contributed to subsequent death. Ten percent of shunts failed during long-term follow-up. The 54% one-year survival by life-table analysis of patients with cirrhosis treated with the Denver shunt matched results previously reported for similar patients treated with the LeVeen shunt. Patients with intra-abdominal malignant neoplasms had an 11% one-year survival overall. Although it too is associated with significant complications, the Denver peritoneovenous shunt seems to have a lower failure rate and a lower incidence of complications than the LeVeen peritoneovenous shunt. Thus, the Denver shunt offers advantages in the treatment of intractable ascites.
回顾了49例连续接受丹佛腹腔静脉分流术治疗患者的记录,以确定并发症的发生率和患者生存时长。在22例(45%)患者中发现了38种并发症(16种类型),其中10例导致了随后的死亡。在长期随访中,10%的分流装置出现故障。通过生命表分析,接受丹佛分流术治疗的肝硬化患者一年生存率为54%,与先前报道的接受LeVeen分流术治疗的类似患者的结果相符。腹腔内恶性肿瘤患者的总体一年生存率为11%。尽管丹佛腹腔静脉分流术也伴有严重并发症,但它似乎比LeVeen腹腔静脉分流术的故障率更低,并发症发生率也更低。因此,丹佛分流术在治疗顽固性腹水中具有优势。